stella
beta
Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies — Stella
Recruiting
Back to T-ALL/Lymphoma trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Trial locations
(1 site)
China
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei
View full record on ClinicalTrials.gov